RT Journal Article
T1 Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment
A1 Ugalde Triviño, Lola
A1 Molina Jiménez, Francisca
A1 H. Vázquez, Juan
A1 Relaño Rupérez, Carlos
A1 Arias González, Laura
A1 Casabona, Sergio
A1 Pérez Fernández, María Teresa
A1 Martín Domínguez, Verónica
A1 Fernández Pacheco, Jennifer
A1 Lucendo, Alfredo J.
A1 Bernardo, David
A1 Santander, Cecilio
A1 Majano Rodríguez, Pedro Lorenzo
AB Objectives. The aim of the study was to characterize the circulating immunome of patients with EoE before and after proton pump inhibitor (PPI) treatment in order to identify potential non-invasive biomarkers of treatment response. Methods.PBMCs from 19 healthy controls and 24 EoE patients were studied using a 39-plex spectral cytometry panel. The plasmacytoid dendritic cell (pDC) population was differentially characterized by spectral cytometry analysis and immunofluorescence assays in esophageal biopsies from 7 healthy controls and 13 EoE patients. Results. Interestingly, EoE patients at baseline had lower levels of circulating pDC compared with controls. Before treatment, patients with EoE who responded to PPI therapy had higher levels of circulating pDC and classical monocytes, compared with non-responders. Moreover, following PPI therapy pDC levels were increased in all EoE patients, while normal levels were only restored in PPI-responding patients. Finally, circulating pDC levels inversely correlated with peak eosinophil count and pDC count in esophageal biopsies. The number of tissue pDCs significantly increased during active EoE, being even higher in non-responder patients when compared to responder patients pre-PPI. pDC levels decreased after PPI intake, being further restored almost to control levels in responder patients post-PPI. Conclusions. We hereby describe a unique immune fingerprint of EoE patients at diagnosis. Moreover, circulating pDC may be also used as a novel non-invasive biomarker to predict subsequent response to PPI treatment.
PB Frontiers Media
SN 1664-3224
YR 2024
FD 2024-04-05
LK https://hdl.handle.net/20.500.14352/118900
UL https://hdl.handle.net/20.500.14352/118900
LA eng
NO Ugalde-Triviño, L., Molina-Jiménez, F., H-Vázquez, J., Relaño-Rupérez, C., Arias-González, L., Casabona, S., Pérez-Fernández, M. T., Martín-Domínguez, V., Fernández-Pacheco, J., Lucendo, A. J., Bernardo, D., Santander, C., & Majano, P. (2024). Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment. Frontiers in Immunology, 15. https://doi.org/10.3389/FIMMU.2024.1374611
NO PM and CS are supported by grants PI17/0008 and ISCIII-Proteored 2019 of Instituto de Salud Carlos III (ISCIII, Spain) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER). CS is also funded by Asociación Española de Gastroenterología (AEG) 2019 grant. DB is funded through the Spanish Ministry of Science [PID2019-104218RB-I00], Programa Estratégico Instituto de Biología y Genética Molecular (IBGM Junta de Castilla y León. Ref. CCVC8485) and the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform. LU-T is recipient of an INVESTIGO contract from Comunidad de Madrid (09-PIN1-00015.6/2022) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan. CR-R is recipient of an INVESTIGO contract from Ministry of Labor and Social Economy, the national public employment service (SEPE) (INVESTIGO Exp. 2022‐C23.I01.P03. S0020‐0000031) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan.
NO Instituto de Salud Carlos III
NO European Commission
NO Asociación Española de Gastroenterología
NO Ministerio de Ciencia e Innovación (España)
NO Junta de Castilla y León
NO Comunidad de Madrid
NO Ministerio de Trabajo y Economía Social (España)
NO Servicio Público de Empleo Estatal (España)
DS Docta Complutense
RD 18 abr 2025